HK1005166A1 - Gabapentin and its derivatives for treating neurodegenerative diseases - Google Patents

Gabapentin and its derivatives for treating neurodegenerative diseases

Info

Publication number
HK1005166A1
HK1005166A1 HK98104232A HK98104232A HK1005166A1 HK 1005166 A1 HK1005166 A1 HK 1005166A1 HK 98104232 A HK98104232 A HK 98104232A HK 98104232 A HK98104232 A HK 98104232A HK 1005166 A1 HK1005166 A1 HK 1005166A1
Authority
HK
Hong Kong
Prior art keywords
gabapentin
treating neurodegenerative
derivatives
neurodegenerative diseases
huntington
Prior art date
Application number
HK98104232A
Other languages
English (en)
Inventor
Geoffrey Neil Woodruff
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27039510&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1005166(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of HK1005166A1 publication Critical patent/HK1005166A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK98104232A 1990-01-02 1998-05-15 Gabapentin and its derivatives for treating neurodegenerative diseases HK1005166A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45991290A 1990-01-02 1990-01-02
US07/615,151 US5084479A (en) 1990-01-02 1990-11-23 Novel methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
HK1005166A1 true HK1005166A1 (en) 1998-12-24

Family

ID=27039510

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98104232A HK1005166A1 (en) 1990-01-02 1998-05-15 Gabapentin and its derivatives for treating neurodegenerative diseases

Country Status (7)

Country Link
US (1) US5084479A (de)
EP (1) EP0446570B1 (de)
JP (1) JP2903434B2 (de)
AT (1) ATE125701T1 (de)
DE (1) DE69111642T2 (de)
DK (1) DK0446570T3 (de)
HK (1) HK1005166A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5217957A (en) * 1991-08-20 1993-06-08 Warner-Lambert Company Cholecystokinin antagonists useful for treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
ATE207878T1 (de) * 1996-03-14 2001-11-15 Warner Lambert Co Zyklische aminosäure als pharmazeutische wirkstoffe
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
PL193237B1 (pl) * 1997-06-30 2007-01-31 Merz Pharma Gmbh & Co Kgaa Pochodne 1-aminoalkilocykloheksanu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
WO1999008667A2 (en) 1997-08-19 1999-02-25 Warner-Lambert Company Methods for treating physiological conditions associated with the use, or sequelae of use, of ***e or other psychomotor stimulants
AU9318398A (en) 1997-10-07 1999-04-27 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
NZ503651A (en) * 1997-10-27 2002-09-27 Warner Lambert Co Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
DE19751062A1 (de) * 1997-11-18 1999-07-08 Univ Ludwigs Albert An 4-Stellung substituierte 2-Pyrrolidinon-Derivate zur Verringerung des extrazellulären Glutamat-Spiegels
US6984659B2 (en) 1997-11-18 2006-01-10 Klinikum Der Albert-Ludwigs Universitaet 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
EP1077692B1 (de) * 1998-05-15 2004-07-28 Warner-Lambert Company LLC Aminosäure-stabilisierte gabapentin und pregabalin zubereitungen und verfahren zu ihrer herstellung
WO1999059572A1 (en) * 1998-05-15 1999-11-25 Warner-Lambert Company Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
FR2801217B1 (fr) * 1999-11-24 2002-12-06 Aventis Pharma Sa Association de riluzole et de gabapentine et son utilisation comme medicament
US6350768B1 (en) 1999-11-24 2002-02-26 Aventis Pharma S.A. Combination of riluzole and of gabapentin and its use as a medicament
AU2001266992B8 (en) * 2000-06-16 2005-12-01 Teva Pharmaceutical Industries Ltd. Stable gabapentin having pH within a controlled range
EP1289364B1 (de) 2000-06-16 2003-12-10 Teva Pharmaceutical Industries Ltd. Stabiles gabapentin, das mehr als 20 ppm chlor enthält
NZ522480A (en) * 2000-06-26 2005-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
WO2002100344A2 (en) * 2001-06-11 2002-12-19 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
HUP0400183A2 (hu) * 2001-06-11 2004-07-28 Xenoport Inc. Gaba-analóg prodrugok csökkentett toxicitású orális dózisformái
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
AU2003210486B2 (en) * 2002-01-16 2007-06-28 Endo Pharmaceuticals Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
US6927036B2 (en) * 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
AU2003262383A1 (en) * 2002-04-16 2003-11-03 Taro Pharmaceutical Industries Ltd. Process for preparing gabapentin
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2005000294A1 (en) * 2003-06-06 2005-01-06 Pharmacia Corporation Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
NZ545989A (en) 2003-09-17 2009-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
MXPA06004088A (es) 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
EP1737466A1 (de) * 2004-01-29 2007-01-03 Pfizer Products Inc. KOMBINATION VON Y-AMINOBUTTERSÄURE-MODULATOREN UND 5HT-1b REZEPTOR-ANTAGONISTEN
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
ITMI20040579A1 (it) * 2004-03-25 2004-06-25 Zambon Spa Processo di preparazione di gabapentina
RU2440112C2 (ru) 2004-11-04 2012-01-20 Ксенопорт, Инк. Пероральная дозированная форма габапентина замедленного высвобождения
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
IN2012MN02923A (de) 2010-06-01 2015-06-05 Rubicon Res Private Ltd
EP2923694B1 (de) 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Orale flüssige pharmazeutische lösung von gabapentin
WO2021079887A1 (ja) * 2019-10-25 2021-04-29 国立大学法人京都大学 タウオパチーの予防又は治療剤
CN115350172A (zh) * 2022-08-12 2022-11-18 昆明医科大学 Gabapentin对AD情景记忆改善的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
ATE125701T1 (de) 1995-08-15
DE69111642T2 (de) 1996-01-25
DK0446570T3 (da) 1995-11-27
JPH04210915A (ja) 1992-08-03
US5084479A (en) 1992-01-28
DE69111642D1 (de) 1995-09-07
EP0446570B1 (de) 1995-08-02
JP2903434B2 (ja) 1999-06-07
EP0446570A3 (en) 1992-04-01
EP0446570A2 (de) 1991-09-18

Similar Documents

Publication Publication Date Title
HK1005166A1 (en) Gabapentin and its derivatives for treating neurodegenerative diseases
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
SE8704204L (sv) Substituerade alfa-aminosyror, deras framstellning och farmaceutiska kompositioner innehallande desamma
MY115977A (en) Synthetic excitatory amino acids
AU4043895A (en) Restricted 9-CIS-retinoids
EP0807633A3 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
EP0552240A4 (en) New method of treating depression
ES2068955T3 (es) Derivados de 1,2,3,4-tetrahidro-9-acridinamina.
HU9402933D0 (en) Neurotensine-receptor-active 1-naphtyl-pyrazol-3-carboxamides process for producing them and pharmaceutical compositions containing them as active components
KR0148212B1 (en) Phenylalkan (en)oic acids
HUT47136A (en) Process for producing cyclic peptides with anticoagulant effect
CA2188176A1 (fr) (oxo-1 alkyl) amino-2, deoxy-2 glucopyranoside de dihydroxy - 2,3 propyl, leur procede de preparation et leurs utilisations
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
AU1237592A (en) Iloprost effective against cerebral malaria
GR3015685T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders.
TW224488B (de)
CZ281393B6 (cs) Způsob výroby 6-(substituovaných amino)-propionyl derivátů forskolinu
HUT56559A (en) Process for producing ascorbinic acid derivatives and pharma
DE69930880D1 (de) Bicyclische(3.1.0)hexane und verwandte Verbindungen
FR2708484B1 (fr) Procédé d'amélioration du broyage des minéraux.
ZA9010083B (en) New process for the preparation of mojirimycin and related compounds
GR3020597T3 (en) Phospholipids for the treatment of multiple sclerosis
DE59101665D1 (de) Verfahren zur Herstellung von staubfreiem Silbernitrat.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090102